Development Office Funding Opportunities

Eligibility:

•Applicant must hold an MD and/or PhD (or equivalent degree) and must be employed by an institution (public non-profit, private non-profit, or government) that is engaged in health care and/or health-related research. He/she must have attained independence from his/her mentor.
•Proposal must be relevant to Inflammatory Bowel Disease (IBD) or Crohn’s disease and/or ulcerative colitis. Only one application is allowed per applicant per submission date. Simultaneous submission of a Senior Research Award and a Training Award is not permitted.

Eligibility:

•Health organizations, academia, medical societies, or professional organizations, in partnership with patient advocacy organizations, that include transthyretin cardiac amyloidosis (ATTR-CM) as one of the focus areas are encouraged to apply.

•The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.

About: This RFP seeks to support medical societies or professional organizations, in partnership with patient advocacy organizations, to develop, validate, and/or evaluate a shared decision-making tool (Decision Aid) aimed at improving decision quality, health outcomes, patient experience, and quality of care among individuals living with ATTR-CM.

Proposals should address all the following areas of interest:

•Tool design and content development consistent with decision-making theory and methodology for SDM tool development and validation.

•Co-development of the tool with stakeholders to ensure relevance, clarity, and acceptability. Input from stakeholders should directly inform content, language, format and practical considerations of the SDM tool. Stakeholders include patients living with ATTR-CM, patient advocacy organizations, caregivers, cardiac amyloidosis specialists such as cardiologists, nurses, and allied HCPs

•Needs assessment and conceptual framework grounded in bidirectional information exchange including literature review and focus groups with stakeholders to identify gaps and decision-making challenges in ATTR-CM care pathway

•Assessment of the tool including tool validity and usability testing with end-users for practical real world clinical use and minimization of unintended barriers to engagement.

Amount: $225,000 over 1 years

Eligibility:

•Have a doctoral degree (including PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.

•Hold a tenure-eligible appointment (or equivalent, if institution does not follow a tenure system) at the rank of assistant professor (appointments such as research assistant professor, adjunct assistant professor, assistant professor research track, visiting professor, or instructor are not eligible. Applicants cannot be tenured or under consideration for a tenured academic position at the time of the application. Applicants that have progressed to associate professor appointments are also not eligible.)

•Have started their first independent faculty position with the title of assistant professor within the past 6 years from the grant start date

About: With generous support from GlaxoSmithKline, the AACR Gertrude B. Elion Cancer Research Award represents a joint effort to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature.

Eligibility:

•Applicants must be AACR Active members who are independent investigators and have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. 

About: Supports independent investigators who are currently conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage independent investigators to enter the TTFields research field. The Inovitro® system (which will be provided by Novocure, if needed), must be included in the experimental design.
Research projects should examine the use of TTFields as a therapeutic modality for cancer. Proposals may include 1) Basic and translational approaches, promoting the transition of TTFields in vitro work into in vivo systems, 2) Studies that link preclinical and clinical data, or 3) Studies with ability to translate into the clinic for cancer treatment.
Projects that focus on one or more of the areas outlined below are strongly encouraged, provided they incorporate the use of Inovitro® and/or inovivo® systems:
• Key cancer-related signaling and cellular pathways.
• Metabolic effects of TTFields.
• Studies that include Omics data (genomics, transcriptomics, proteomics).
• TTFields immunological aspects and the potential combination with immunotherapy.
• Combinational studies with approved agents (preferably to include mechanistic aspects).

Eligibility: —

About: SPARK NS is an independent non-profit translational research organization dedicated to efficiently advancing promising neuroscience discoveries from the lab to the clinic.

For the SPARK NS Translational Research Program, 2026 Cohort, SPARK NS will select academic PIs with therapeutic discoveries in Parkinson’s disease or autism at any stage of development between target identification and entry into clinical trials. For selected projects, SPARK NS will provide funding, education, mentorship, and networking opportunities focused on advancing the translation of novel science to first-in-class therapeutics.

Proposed projects must:
• Address an unmet clinical need in Parkinson’s disease or autism
• Use a robust and novel approach
• Have a high probability of success at accomplishing proposed translational objectives

Eligibility:
•For pre-doctoral applicants:
Applicant must be enrolled in a research doctoral degree program at an accredited academic institution.

•For post-doctoral applicants:
Applicant must hold an M.D. and/or Ph.D. by the application deadline.
Applicant must be no more than 6 years post-completion of last degree.

Eligibility:

•Have obtained a PhD or equivalent degree at least 5 years (excluding career breaks) prior to the application deadline; 

•Be employed by and be part of a research lab at an institution of higher education or research institute;

•Be conducting high-quality research in the area of variability of learning and development;

•Be committed to engaging with and contributing to the activities of both LEVANTE and the Jacobs Foundation.

About:  The overarching objective of LEVANTE is to identify how individual variability, group heterogeneity, and contextual variability influence children’s learning and development. By including data collection of common measures on these different areas longitudinally and at a global level, LEVANTE will help researchers, educators, and policymakers understand child development within individuals, within groups, and across contexts, thus improving future learning outcomes for diverse groups of children worldwide. The focus of the Jacobs Foundation is fostering scientific excellence and building a strong network of internationally active researchers in the field of child and youth development with a strong focus on variability of learning and to foster long-term collaboration with other researchers and the Jacobs Foundation.

This call seeks proposals for research projects that collect longitudinal data using the LEVANTE battery across ages 3–12. Within this framework, special consideration will be given to proposals that

•Contribute to causal inference on mechanisms underlying learning and development, and/or generate insights into how environmental and contextual factors shape learning
•Strengthen the use of innovative, high-resolution measurement approaches and/ or advance our understanding of within-child variability and developmental trajectories

Amount: $130,000 over 2 years

Eligibility:

•Applicants must have a doctoral degree (including PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.

•At the start of the grant term applicants must:
oHold a mentored research position with the title of postdoctoral fellow, clinical research fellow, or the equivalent
oIf eligibility is based on a future position, the position must be confirmed at the time of submission, and CANNOT be contingent upon receiving this grant.
oIf the future position is at a different institution than the applicant’s current institution, the applicant must contact AACR’s Research and Grants Administration Department (AACR’s RGA) at grants@aacr.org before submitting their application for information on additional verification materials/signatures that may be required.
oHave completed their most recent doctoral degree within the past 5 years (i.e., degree cannot have been conferred before September 1, 2021; the formal date of receipt of doctoral degree is the date the degree was conferred, as indicated on your diploma and/or transcript)
oApplicants with a medical degree must have completed their most recent doctoral degree or medical residency – whichever date is later – within the past five years.
oWork under the auspices of a mentor at an academic, medical, or research institution anywhere in the world.

About: Supports a postdoctoral or clinical research fellow to conduct renal cell carcinoma research and to establish a successful career path in this field. The research proposed for funding may be in basic, translational, clinical, or population sciences research and must have direct applicability and relevance to renal cell carcinoma

Deadline: June 15, 2026

Eligibility:
The applicant (MD, PhD, PharmD, or equivalent) must hold an academic faculty appointment and be developing an independent research program
Applicants cannot be a PI on a previous or current NIH grant to perform independent research.
Applications are accepted in basic, clinical, and translational research. Only applications supporting research directly related to solid organ transplantation will be considered.

Deadline:
• LOI due July 15, 2026
• Full proposal deadline TBD

Eligibility:

• Grant applicants must possess a graduate degree
• Must not have received a Shaffer Grant within the prior three years

About: Supports young investigators with new perspectives to treat and cure glaucoma. There are two primary focus areas that this grant will fund:

1.Physiology of Glaucoma: May include projects to protect and restore the optic nerve, accurately detect glaucoma and monitor its progress, provide better understanding and treatment for congenital/juvenile glaucoma, understand the intraocular pressure system and develop better treatments, and determine the risk factors for glaucoma damage using systematic outcomes data.

2.Genetics of Glaucoma: May include projects to identify the genes that cause glaucoma and explore new approaches to gene therapy to preserve or restore vision 

Eligibility:

An applicant may be a postdoctoral research fellow, postgraduate medical trainee, junior faculty, or established investigator. The LAM Foundation encourages applications from investigators new to LAM research who could contribute their knowledge and expertise.

Eligibility:

•An applicant may be a clinical fellow, clinical instructor, postdoctoral research fellow, postgraduate medical trainee, junior faculty or established investigator.

Eligibility:

Department Chairs (including interim or acting Chairs) from any institution of higher education in the U.S. may nominate multiple candidates per department.
Though multiple candidates can be nominated from one department, only one award per department can be approved.
Candidates must hold a primary academic position as Associate Professor through full Professor (MD, PhD, or MD/PhD) with a primary appointment in a basic science or other relevant department.
Previous recipients of this grant are ineligible.
Candidates must be full-time faculty in their primary appointment department.
Proposed research cannot be funded – previously or currently – by others (NEI, NIH, nonprofits, private funders, etc.).
Candidates declined for this award must wait two years before re-applying for the SI Award. 

Eligibility:

Department Chairs (including interim or acting Chairs) from any institution of higher education in the U.S. may nominate multiple candidates per department.
Though multiple candidates can be nominated from one department, only one award per department can be approved.
Candidates must hold a primary academic position as Associate Professor through full Professor (MD, PhD, or MD/PhD) with a primary appointment in a basic science or other relevant department.
Previous recipients of this grant are ineligible.
Candidates must be full-time faculty in their primary appointment department.
Proposed research cannot be funded – previously or currently – by others (NEI, NIH, nonprofits, private funders, etc.).
Candidates declined for this award must wait two years before re-applying for the SI Award. 

Eligibility:

•Applicants must have an independent faculty appointment (tenure-track or equivalent) at a non-profit academic/research institution.
•Collaboration teams must consist of one principal investigator (PI) at the host institution and one co-principal investigator (co-PI) at a different institution. We encourage teams that bring together individuals with distinct expertise (e.g. a cancer investigator and computational expert, a cancer investigator and an aging expert who has not previously worked in the cancer field, or experts who study aging in oncology and immunology).
•The PI and co-PI must both lead established laboratories currently supported by multi-year independent funding. For example, for US-based applicants, this should be at least one R01 or R01-equivalent grant. International applicants should similarly demonstrate independent support for their labs.
•Investigators who currently hold “Aging and Cancer” awards from the Mark Foundation are not permitted to apply.
•The PI and co-PI can only participate in one application, regardless of role.

About: Research supported by this program will advance our understanding of the rising incidence of cancer due to aging, with a special emphasis on the role of inflammaging and immunosenescence as common drivers of aging and cancer. Example topics include but are not limited to:

•Identifying actionable biomarkers (inflammatory molecules, immune cells, etc.) that link aging and cancer risk, including in younger individuals with early onset cancers and those with genetic predispositions, and underlying mechanisms.

•Dissecting the effects of the aging tumor microenvironment (e.g., inflammation, immune system, senescent cells) on tumorigenesis, progression, and treatment response.

•Investigating how progression of age-related clonal hematopoiesis, myeloid skewing, or emergency myelopoiesis promotes hematological malignancies (including chronic myelomonocytic leukemia) or solid tumors, and/or causes therapeutic resistance.

•Establishing the effects of tumors and cancer therapies in organismal aging, including the identification of biomarkers and therapeutic strategies to minimize or prevent cancer-induced aging.

•Providing preclinical and mechanistic validation for aging-specific, anticancer therapeutic approaches based on strategies targeting inflammation or senescence, or nominated from clinical trial data segregated by age.

•Supporting exploratory clinical trials to treat or prevent cancer in older or high-risk individuals, including correlative analyses from clinical samples derived from relevant trials. We encourage collaborations with biopharma or other funding sources to accelerate the proposed work.

Eligibility:
We welcome proposals from:

• LMIC-based institutions

• Partnerships led by LMIC institutions

• Global consortia that include meaningful LMIC partner engagement and capacity development

About: Through this Grand Challenge, the Foundation seeks to support organizations with strong epidemiologic and quantitative modeling capabilities to produce credible, transparent, and decision-useful estimates of diarrheal disease burden in LMICs. Applicants should propose approaches that can generate a minimum core set of estimates for the year 2025 and, where feasible, build longer-term analytic capacity in LMICs.

Proposals must include plans to generate, at minimum:

•Country-specific estimates of total diarrheal mortality burden in children under five.

•Country-specific pathogen-attributed mortality burden for children under five.

•Estimates reported as both total number of diarrhea-attributed deaths, pathogenspecific fractions, and mortality incidence rates, centered on 2025, using the most recent available data and appropriate methods for projection, interpolation, or extrapolation where needed.

•When possible, country-specific estimates of total and/or pathogen-attributed morbidity burden, measured as all cause or pathogen-specific disease cases, severe disease cases, or hospitalizations and presented as the total numbers, pathogenspecific fractions, and/or incidence rates.

•Estimates reported as point estimates with confidence/uncertainty intervals.

•Geographic scope: may include proposed estimates for a single country, region, all LMICs, or global. While proposals may focus on a single country, region, all LMICs, or global estimates, preference will be given to proposals focused on geographies where diarrheal mortality is expected to be highest or where improved estimates of both mortality and morbidity would have particularly high programmatic relevance, including but not limited to India, Nigeria, and sub-Saharan Africa.

Eligibility:

•Have received a Ph.D. (or D.Phil. or equivalent) degree no more than 2 years before the application deadline, or an M.D. (or M.D.-Ph.D.) degree no more than four years before the deadline
•They have been employed in their postdoctoral laboratory for no more than 1 year before the application deadline.
•The Foundation will not make more than one award per year for training with a given supervisor. Should we receive more than one application from a single laboratory, we will review only one, as chosen by the Chair of the SAC, and decline the other(s) administratively. We urge the heads of laboratories to make this choice for us.

Deadline:
•LOI due June 23, 2026
•Full proposal due July 23, 2026

Eligibility:

•The applicant who wishes to take on the Principal Investigator position must have a faculty appointment at the institution
•Proposal must be relevant to IBD, which includes  Crohn’s disease and/or ulcerative colitis
•Only one application is allowed per applicant per submission date
•Simultaneous submission of the same application for other awards is not permitted

Eligibility:

•Individuals who are already well established in the field of IBD research are not considered eligible for this award.
•Applicants should identify a senior investigator to act as a mentor to facilitate the transition to independence.
•Applicants must hold an MD and/or PhD (or equivalent degree).
oCandidates holding MD degrees must have 5 years of experience after receiving their terminal degree—two years of which must be documented research experience relevant to IBD.
oApplicants holding PhDs must have at least 2 years of documented post-doctoral research relevant to IBD.
•Generally, candidates should not be in excess of 10 years beyond the attainment of their doctoral degree.

Eligibility:

•Individuals who are already well established in the field of IBD research are not considered eligible for this award.

•Applicants should identify a senior investigator to serve as a mentor throughout the term of the award.

•Applicants must hold an MD and/or PhD (or equivalent degree).
oCandidates holding MD degrees must have 2 years of experience after receiving their terminal degree —1 year of which must be documented research experience relevant to IBD.
oApplicants holding PhDs must have at least 1 year of documented post-doctoral research relevant to IBD. MD applicants in excess of 7 years and PhD applicants in excess of 5 years of receiving their terminal degree should explain how additional support in the post-doctoral phase would benefit their development beyond their current training.

•Proposals MUST be relevant to IBD (Crohn’s Disease or ulcerative colitis) and must include a training and a mentoring plan. Only one application is allowed per applicant per submission date. Simultaneous submission of a Senior Research Award and a Research Training Award is not permitted.

•Awardees must devote a minimum of 80% of his/her professional time directly to the project